AVROBIO is a clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. AVROBIO’s gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. AVROBIO’s approach is designed to transform stem cells from patients into therapeutic products, and has the potential to provide curative benefit for a range of diseases.

Goodwin began working with the co-founder and CEO of AVROBIO, Geoff MacKay in 2015, creating and filing incorporation papers. Mr. MacKay previously served as interim chief executive officer of eGenesis, Inc. and as chief executive officer of Organogenesis, Inc. Goodwin served as outside counsel for the Company through its early years by advising AVROBIO in securing early-stage seed financing with Atlas Venture and establishing its foundational in-licenses. Goodwin also acted as AVROBIO’s counsel for its $25 million Series A financing in July 2016 through October 2017, and its $60 million crossover financing in January 2018. Goodwin shepherded AVROBIO in its $115 million IPO in June 2018, and continues to serve as outside general counsel for the Company. Goodwin’s relationship with AVROBIO showcases the depth and breadth of the firm’s practice in the life sciences industry, offering to clients like AVROBIO an integrated and collaborative team of attorneys across multiple practice areas, including life sciences, emerging companies, corporate governance, securities, capital markets, licensing, tax, employment and benefits.